

ABOUT CHERYL SELINSKY, PhD – VP, RESEARCH OPERATIONS

Cheryl Selinsky, PhD, is the vice president of research operations at the Parker Institute for Cancer Immunotherapy.

Dr. Selinsky earned her doctorate in immunology at Colorado State University and has more than 20 years of experience in translational research and product & technology development. She began her career investigating the role of immune system inhibitors in the development and persistence of cancer, and she co-founded a biotechnology company to promote the commercialization of novel cancer immunotherapeutics targeted at the selective removal of these immune system inhibitors from the blood circulation of cancer patients. She has subsequently applied her industry experience to preclinical and clinical evaluation of vaccines for infectious diseases and cancer, and has developed and managed CLIA-certified and GLP-compliant laboratories in support of clinical trials.

Prior to joining the Parker Institute, Dr. Selinsky was the chief operating officer of the Biodesign Institute at ASU. Her appointment as COO added to her previous experience as a research scientist within the Institute's Center for Innovations in Medicine. Since her initial appointment at the Biodesign Institute, Dr. Selinsky has served as the senior director for Translational Research Development at the Phoenix-based Translational Genomics Research Institute (TGen) and as the director of Technical Operations during the development and implementation of a state of the art proteomics facility at TGen. This facility uses mass spectrometry-based validation of protein-based biomarkers for cancer and infectious diseases. She served as the program director for TGen's partnership with the Multiple Myeloma Research Foundation in a prospective, longitudinal study to assess the relationship between patient outcomes, treatment regimens and molecular profiles. Dr. Selinsky was a member of the TGen Stand Up to Cancer/Melanoma Research Alliance Melanoma Dream Team who, in collaboration with more than a dozen clinical sites, launched the first of its kind clinical trial to examine the genomes of metastatic melanomas. The ongoing trial focuses on DNA- and RNA-based interrogation to align specific genomic and transcriptomic alterations in these cancers with appropriate targeted therapies.

Dr. Selinsky also directed the Biospecimen Core Repository for the National Cancer Institute's The Cancer Genome Atlas program. She managed the laboratory responsible for the processing, quality control and quality assurance of all cancer cases submitted to the project during its 3-year pilot phase and developed many of the standard operating procedures still in use by the project today. Dr. Selinsky brings to the Parker Institute her diverse experience as a scientist in both academic and industry settings, as well as her expertise in preclinical and clinical research, laboratory and administrative operations, strategic planning and program management.